Fu ZG, Ren ZX, Wang XH, Wang BF. Investigation of gastrointestinal tumor symptoms and risk factors in eighty patients with Parkinson’s disease. World J Gastrointest Oncol 2025; 17(9): 106912 [DOI: 10.4251/wjgo.v17.i9.106912]
Corresponding Author of This Article
Zhong-Guo Fu, PhD, Department of Neurology, The First People’s Hospital of Shenyang, No. 67 Qingquan Road, Dadong District, Shenyang 110041, Liaoning Province, China. fzg15940517539@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 106912 Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.106912
Investigation of gastrointestinal tumor symptoms and risk factors in eighty patients with Parkinson’s disease
Zhong-Guo Fu, Zhan-Xiu Ren, Xin-Hong Wang, Bai-Fang Wang
Zhong-Guo Fu, Department of Neurology, The First People’s Hospital of Shenyang, Shenyang 110041, Liaoning Province, China
Zhan-Xiu Ren, Department of Neurology, The People’s Hospital of Liaoning Province, Shenyang 110041, Liaoning Province, China
Xin-Hong Wang, Department of Neurology, General Hospital of Northern Theatre Command, Shenyang 110041, Liaoning Province, China
Bai-Fang Wang, Department of Endoscopy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110041, Liaoning Province, China
Author contributions: Fu ZG designed the study and was involved in data collection and manuscript preparation; Fu ZG, Ren ZX, Wang XH, and Wang BF contributed to the review of the manuscript; and all authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Medical Ethics Committee of the First People’s Hospital of Shenyang, China.
Informed consent statement: All study participants and their legal guardians provided written informed consent before enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhong-Guo Fu, PhD, Department of Neurology, The First People’s Hospital of Shenyang, No. 67 Qingquan Road, Dadong District, Shenyang 110041, Liaoning Province, China. fzg15940517539@126.com
Received: May 9, 2025 Revised: June 6, 2025 Accepted: August 4, 2025 Published online: September 15, 2025 Processing time: 128 Days and 18.2 Hours
Abstract
BACKGROUND
Parkinson’s disease (PD) is often accompanied by gastrointestinal symptoms; however, the relationship between PD and gastrointestinal tumors remains unclear.
AIM
To explore the symptom characteristics and risk factors of gastrointestinal tumors in patients with PD by integrating clinical, neurological, gastrointestinal, and laboratory assessments.
METHODS
Eighty patients with PD who were admitted to our hospital between January 2023 and December 2024 were retrospectively analyzed. Clinical characteristics and neurological status were evaluated using standardized scales, including the Mini-Mental State Examination, Depression Anxiety Stress Scale-21, Pittsburgh Sleep Quality Index Barthel Index, Non-Motor Symptoms Scale, and the Intake, Feeling nauseated, Emesis, physical Exam, Duration of symptoms (I-FEED) gastrointestinal dysfunction score. Laboratory indicators including tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 72-4 (CA72-4)] were measured. Differences between PD patients with and without gastrointestinal tumors were compared, and logistic regression was used to identify associated factors.
RESULTS
Among the 80 PD patients, 16 (20.00%) had gastrointestinal tumors. The most common symptoms in the tumor group were constipation (93.75%), urgency of defecation (75.00%), and abdominal tightness (75.00%). Patients with gastrointestinal tumors had significantly higher I-FEED, CEA, CA19-9, and CA72-4 levels (P < 0.05). Logistic regression revealed that sex, disease duration, I-FEED score, and the levels of CEA, CA19-9, and CA72-4 were independently associated with the presence of gastrointestinal tumors, while Non-Motor Symptoms Scale was not significantly related.
CONCLUSION
This study uniquely combines neurological symptom scales and tumor markers to evaluate gastrointestinal tumor risk in patients with PD. The findings suggest that gastrointestinal dysfunction and tumor marker elevation are key clinical indicators, and highlight the importance of comprehensive assessment in identifying high-risk PD patients for timely intervention.
Core Tip: This study investigated 80 patients diagnosed with Parkinson’s disease and revealed that approximately 20% of them had coexisting gastrointestinal tumors. Common symptoms included constipation and urgent bowel movements. The presence of tumors was significantly associated with factors such as sex, disease duration, gastrointestinal function scores, and elevated levels of multiple tumor markers, offering insight into early identification of high-risk patients.
